Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a US-based biopharmaceutical company dedicated to developing therapies for rare neurological disorders, focusing on enzyme replacement therapy for conditions like Mucopolysaccharidosis Type IIIB (MPS IIIB). Established in 2016 and headquartered in San Francisco, US, Spruce Biosciences, Inc. focuses on enzyme replacement therapies.

The company is headed by its CEO Javier Szwarcberg serving as of 2026. In January 2026, Spruce Biosciences, Inc. raised USD 15 million in venture debt funding from Avenue Capital. Spruce Biosciences specializes in developing innovative therapies aimed at treating rare neurological disorders, with a focus on enzyme replacement therapy.

Their lead product, Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT), targets Mucopolysaccharidosis Type IIIB (MPS IIIB), addressing the underlying biochemical deficiency that leads to the progression of the disease. The company primarily serves the patients and families affected by MPS IIIB and related conditions, marketing its products in North America and Europe, which have a recognized demand for specialized treatments for rare diseases. The revenue is generated primarily through the commercialization of TA-ERT, with a business model that involves partnerships with healthcare providers and institutions, facilitating patient access to its therapies. The pricing model for TA-ERT aligns with industry standards for rare disease treatments and reflects the complexity of the therapy.

The company will use the January 2026 funding to support the filing of the biologics license application for TA‑ERT and accelerate pre‑launch commercial activities.